Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Colorectal Cancer, Cancer, Cancer, Cancer, Cancer, Endocrine, Thyroid Cancer
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:12 - Any
Updated:4/3/2019
Start Date:May 9, 2017
End Date:December 2019
Contact:Patient Advocacy
Email:clinicaltrials@loxooncology.com
Phone:855-RET-4-292 (855-738-4292)

Use our guide to learn which trials are right for you!

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety,
tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of LOXO-292
administered orally to patients with advanced solid tumors, including RET-fusion-positive
solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors,
including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The
trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion).
Patients with advanced cancer are eligible if they have progressed on or are intolerant to
available standard therapies, or no standard or available curative therapy exists, or in the
opinion of the Investigator, they would be unlikely to tolerate or derive significant
clinical benefit from appropriate standard of care therapy, or they declined standard
therapy. A dose of 160 mg BID has been selected as the recommended phase 2 dose (RP2D). Up to
~750 patients with advanced solid tumors harboring a RET gene alteration in tumor and/or
blood will be enrolled to one of five phase 2 cohorts.

Key Inclusion Criteria:

For Phase 1

- Patients with a locally advanced or metastatic solid tumor who:

- have progressed on or are intolerant to standard therapy, or

- no standard therapy exists, or in the opinion of the Investigator, are not
candidates for or would be unlikely to tolerate or derive significant clinical
benefit from standard therapy, or

- decline standard therapy

- Prior MKIs with anti-RET activity are allowed. However, prior treatment with a
selective RET inhibitor(s) is prohibited.

- A RET gene alteration is not required initially. Once adequate PK exposure is
achieved, evidence of RET gene alteration in tumor and/or blood is required as
identified through molecular assays, as performed for clinical evaluation.

- Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as
appropriate to tumor type.

- Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance
Score (LPS) ≥ 40% (age < 16 years) with no sudden deterioration 2 weeks prior to the
first dose of study treatment.

- Adequate hematologic, hepatic and renal function.

- Life expectancy of at least 3 months.

For Phase 2

As for phase 1 with the following modifications:

- For Cohorts 1 and 3 Subjects must have received prior standard therapy appropriate for
their tumor type and stage of disease, or in the opinion of the Investigator, would be
unlikely to tolerate or derive clinical benefit from appropriate standard of care
therapy.

- Cohorts 1-4: enrollment will be restricted to patients with evidence of a RET gene
alteration in tumor. However, a positive germline DNA test for a RET gene mutation is
acceptable in the absence of tumor tissue testing for patients with MTC.

- Cohorts 1-4: at least one measurable lesion as defined by RECIST 1.1 or RANO, as
appropriate to tumor type and not previously irradiated.

- Cohort 4: radiographic PD within the previous 14 months.

Note: Patients otherwise eligible for cohort 4 who do not demonstrate radiographic PD
within the previous 14 months may be enrolled to cohort 5 if a compelling rationale is
provided by the investigator and approved by the Sponsor.

Cohort 5: (up to 150 patients):

- Cohorts 1-4 without measurable disease;

- MTC not meeting the requirements for Cohorts 3 or 4; (a known RET mutation is not
required)

- MTC syndrome spectrum cancers (e.g. MTC, pheochromocytoma) or poorly differentiated
thyroid cancers with other RET alteration/activation may be allowed with prior Sponsor
approval;

- cfDNA positive for a RET gene alteration not known to be present in a tumor sample.

Key Exclusion Criteria (Phase 1 and Phase 2):

- Phase 2 Cohorts 1-4: an additional known oncogenic driver.

- Prior treatment with a selective RET inhibitor

- Investigational agent or anticancer therapy within 5 half-lives or 2 weeks (whichever
is shorter) prior to planned start of LOXO-292. In addition, no concurrent
investigational anti-cancer therapy is permitted. LOXO-292 may be started within less
than 5 half-lives or 2 weeks of prior therapy if considered by the Investigator to be
safe and within the best interest of the patient, with prior Sponsor approval.

- Major surgery (excluding placement of vascular access) within 4 weeks prior to planned
start of LOXO-292.

- Radiotherapy with a limited field of radiation for palliation within 1 week of planned
start of LOXO-292, with the exception of patients receiving radiation to more than 30%
of the bone marrow or with a wide field of radiation, which must be completed at least
4 weeks prior to the first dose of study treatment.

- Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of
starting study treatment with the exception of alopecia and Grade 2, prior
platinum-therapy related neuropathy.

- Symptomatic primary CNS tumor, metastases, leptomeningeal carcinomatosis, or untreated
spinal cord compression. Patients are eligible if neurological symptoms and CNS
imaging are stable and steroid dose is stable for 14 days prior to the first dose of
LOXO-292 and no CNS surgery or radiation has been performed for 28 days, 14 days if
stereotactic radiosurgery [SRS].

- Clinically significant active cardiovascular disease or history of myocardial
infarction within 6 months prior to planned start of LOXO-292 or prolongation of the
QT interval corrected (QTcF) > 470 msec on all 3 ECGs during Screening.

- Required treatment with certain strong CYP3A4 inhibitors or inducers.
We found this trial at
37
sites
Newport Beach, California 92658
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
(404) 727-5640
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Chicago, Illinois 60637
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
235 North Belle Mead Avenue
East Setauket, New York 11733
?
mi
from
East Setauket, NY
Click here to add this to my saved trials
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
600 Highland Ave.
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Carbone Cancer Center UW Carbone Cancer Center holds the unique distinction of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Melbourne,
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oakland, California 94611
?
mi
from
Oakland, CA
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
714-456-7890
University of California, Irvine Medical Center We are UC Irvine Health. We are a devoted...
?
mi
from
Orange, CA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
6600 Bruceville Road
Sacramento, California 95823
(916) 688-2000
Kaiser Permanente - Sacramento At the Kaiser Permanente South Sacramento Medical Center, you and your...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Salt Lake City, Utah 84112
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
5777 E Mayo Blvd
Scottsdale, Arizona 85259
(480) 515-6296
Mayo Clinic Scottsdale Mayo Clinic Arizona was the second Mayo practice to be established outside...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Vallejo, California 94589
?
mi
from
Vallejo, CA
Click here to add this to my saved trials